Expert Insights Into the Management of MPNs : Episode 14

Opinion

Video

August 7, 2023

Exploring the Future of MF Treatment

Author(s):

The panel closes their discussion by highlighting novel agents in the treatment of myeloproliferative neoplasms to look out for.

EP: 1.An Overview of Myeloproliferative Neoplasms (MPNs)

EP: 2.Risk Assessment for Patients with Polycythemia Vera (PV)

EP: 3.Current Treatment Landscape for Patients With PV

EP: 4.Selecting a Frontline Therapy for Patients With PV

EP: 5.Ruxolitinib for the Management of PV

EP: 6.Ropeginterferon alfa-2b for the Treatment of PV

EP: 7.Reviewing the Types of Myelofibrosis

EP: 8.The Role of Transplant in the Treatment of Patients With MF

EP: 9.COMFORT-I and COMFORT-II Data Review

EP: 10.Pacritinib and Fedratinib for the Treatment of MF

EP: 11.Sequencing Therapies in Patients with MF

EP: 12.Considering Toxicities and Side Effects of JAK Inhibitors in Patients with MF

EP: 13.Symptom Monitoring in Patients with MF

Now Viewing

EP: 14.Exploring the Future of MF Treatment

Related Content

November 15th 2024

Venetoclax Plus 10-Day Decitabine Produces Responses in High-Risk MDS, AML

March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

November 13th 2024

Tamibarotene Plus Azacitidine Fails to Improve CR Rates in High-Risk, RARA+ MDS

November 20th 2023

FDA Approval Insights: Ivosidenib in R/R IDH1+ Myelodysplastic Syndrome

Ruxolitinib plus low-dose pegylated interferon alfa-2a is well tolerated and efficacious in patients with newly diagnosed polycythemia vera.

November 5th 2024

Ruxolitinib Plus Pegylated Interferon Alfa-2a Is Safe and Effective in Newly-Diagnosed PV

Daniel DeAngelo MD, PhD, of Dana-Farber Cancer Institute

October 28th 2024

JAK Inhibitors Remain the Gold Standard in Myelofibrosis